Alluvi Tirzepatide

Alluvi Tirzepatide

Alluvi Tirzepatide 40 mg is a product sold online (primarily via multiple UK and US hosted sites) as a pre-filled multi-dose “research pen” containing a total of 40 mg of tirzepatide, typically described as supporting weekly doses in the 2.5–10 mg range and marketed as a 12–16 week supply.Important product and vendor information

The sites that sell it clearly label it as “R&D only – not for human or veterinary use.” However, customer reviews and marketing language frequently mention personal use for weight loss.

Alluvi Tirzepatide 40MG – Tirzepatide Pen

There are a number of websites claiming to be the “official” Alluvi source, with the brand linked to many domains, Telegram channels, and social-media promotions. There are also many reports of impersonator/scam sites requesting additional payments (customs fees, etc.).
Regulatory action:

1. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has seized several Alluvi-branded pens labelled as tirzepatide and retatrutide, along with manufacturing equipment and raw materials in a series of raids, including at sites in Northamptonshire. A court has frozen more than £200,000 held in accounts linked to the brand as part of an ongoing investigation into illegal/unlicensed weight-loss injections.

These are not the licensed drugs Mounjaro or Zepbound (both of which contain tirzepatide and are made by Eli Lilly). Unlicensed versions sold as “research chemicals” are not under the same controls for manufacturing, purity, sterility or dosing.tirzepatide itself (approved drug)Tirzepatide is a dual GLP-1/GIP receptor agonist that is approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

Alluvi Tirzepatide Pen – Alluvi Tirzepatide Reviews 

Adults: Suggested Dosage:
Initial: 2.5 mg once weekly x 4 weeks
Increase by 2.5 mg increments every ≥4 weeks
Max. approved dose: 15 mg once weekly

The 40 mg dose has not been approved. A 40 mg pen is merely a multi-dose device that holds a total amount that can be dialled down into smaller weekly amounts. Off-label use of >15 mg, and the clinical trials that led to the approval do not have safety/efficacy data to support such use.Common side effects (especially when the dose is being increased) are nausea, vomiting, diarrhoea, constipation and loss of appetite. Serious risks include pancreatitis, gallbladder problems, possible thyroid C-cell tumours (boxed warning based on rodent data) and kidney problems from dehydration.Important safety and legal information

Where To Buy Alluvi Tirzepatide Online – Buy Alluvi Tirzepatide Uk 

Buying and using unlicensed injectable products are extremely dangerous: the purity is unknown, the dose is unknown, the product may be contaminated and there is no medical supervision.
In the UK and many other countries, the supply or possession of these products for human use outside of regulated channels is illegal.
Authentic tirzepatide (Mounjaro/Zepbound) is prescribed by a licensed clinician and dispensed by regulated pharmacies.

Alluvi Healthcare’s 40 mg tirzepatide pens are unlicensed research-chemical products and have been the subject of MHRA enforcement action. They are not the same as the approved medicines. If you are thinking of using tirzepatide for a medical reason, you should see a doctor and obtain an appropriate, regulated prescription product.